Table 2 Echocardiographic data and force-frequency relationship during dobutamine echo
Left Ventricular EDV (ml) | 108 ± 28 |
Left Ventricular ESV rest (ml/m2) | 23 ± 8 |
Left Ventricular ESV peak (ml/m2) | 11 ± 6 |
Systolic Pressure rest (mmHg) | 127 ± 13 |
Systolic Pressure peak (mmHg) | 160 ± 27 |
SP/ESV index (rest) | 6.22 ± 2.53 |
SP/ESV index (peak) | 17.03 ± 7.88 |
ESPVR slope (χ 10-2) | 21.1 ± 7.3 |
Δ peak – rest (mmHg/ml) | 10.85 ± 6.9 |
Heart rate rest (b.p.m.) | 82 ± 6 |
Heart rate peak (b.p.m.) | 129 ± 15 |
Left Ventricular Ejection fraction (rest, %) | 59 ± 8 |
Left Ventricular Ejection fraction (peak, %) | 72 ± 9 |
Double product (rest) | 10437 ± 1396 |
Double product (peak) | 20838 ± 3481 |
Ischaemia during Dobutamine, n (%) | 3 (12%) |
Flat-biphasic ESPVR during Dobutamine, n (%) | 4 (16%) |
Critical Heart Rate (b.p.m.) | 123 ± 17 |
Dobutamine dose 40 μg, n (%) | 22 (88%) |
Dobutamine dose 30 μg, n (%) | 3 (12%) |
On therapy at the time of stress: | |
Everolimus | 10 (40%) |
Tacrolimus | 5 (20%) |
Cyclosporine | 22 (88%) |
Mycophenolate mofetil | 14 (56%) |
Cortisone | 3 (12%) |
Ca-Channel Blocker | 6 (24%) |
Nitrates | 3 (12%) |
B-Blocker | 19 (76%) |
Diuretics | 12 (48%) |
Acetyl salicylic acid | 23 (92%) |
Amiodarone | 1 (4%) |
ACE-I | 13 (52%) |
ARBs | 2 (8%) |
Statins | 23 (92%) |